Form 4: CEO Brian Webster Sells 15,000 Kestra Medical Shares

Kestra Medical Technologies CEO Brian Webster sold 15,000 common shares at a weighted average price of $20.0447.

Summary

• Brian Daniel Webster, President and CEO of Kestra Medical Technologies, sold 15,000 common shares on April 15, 2026.
• The shares were sold at a weighted average price of $20.0447, with individual transaction prices ranging from $20.00 to $20.22.
• Following this transaction, Webster retains beneficial ownership of 349,786 common shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a routine divestment rather than a reactive move.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which typically indicates the transaction was planned in advance for liquidity purposes rather than based on non-public information.

Negatives

• Insider selling by a CEO can sometimes be perceived by the market as a lack of confidence in the short-term stock price appreciation, despite the pre-planned nature of the sale.

Risks

• Market volatility affecting the share price of Kestra Medical Technologies.
• Potential negative investor sentiment resulting from executive divestment.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Management Comments

• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard industry practice for executives to avoid potential insider trading allegations.
• The volume of shares sold represents a small fraction of the CEO's total holdings, which is consistent with typical executive diversification strategies.

Stakeholder Impact

• Shareholders may monitor the stock price for potential volatility following the disclosure of executive selling.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Kestra Medical Technologies, KMTS, Insider Trading, Form 4, Brian Webster, Stock Sale, Rule 10b5-1